<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03062384</url>
  </required_header>
  <id_info>
    <org_study_id>15 0534 F6A</org_study_id>
    <nct_id>NCT03062384</nct_id>
  </id_info>
  <brief_title>AT-001 for Long-term Preservation of Brain Health in Aging</brief_title>
  <acronym>ALPHA</acronym>
  <official_title>AT-001 for Long-term Preservation of Brain Health in Aging: The ALPHA Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kentucky</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alltech Life Sciences Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kentucky</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate if the use of a yeast-selenium supplement (AT-001)&#xD;
      is safe in elderly subjects who do not have dementia, and further, to see if the supplement&#xD;
      improves tests that are related to brain health.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Double blind, placebo-controlled, single-center study. Approximately 40 healthy volunteers&#xD;
      will be randomized to the study drug and 20 healthy volunteers randomized to the placebo, for&#xD;
      a total of 60 enrolled participants.&#xD;
&#xD;
      All participants will be treated with the study drug or placebo for 12 months. Subjects will&#xD;
      be seen in the clinic for the following visits: Screening (Day -14), Baseline (Day 0), Month&#xD;
      6, and End-of-Study (Month 12) while on study drug. An additional safety visit at Month 13&#xD;
      (four weeks after study drug discontinuation) will be required of all participants.&#xD;
&#xD;
      Participants will undergo vital signs assessment, medical history review, medication list&#xD;
      review, and review of Adverse Events (AEs) and Serious Adverse Events (SAEs) at each visit.&#xD;
&#xD;
      Participants will undergo neuropsychological testing and routine physical examinations at the&#xD;
      screening, baseline, and end-of-study visits.&#xD;
&#xD;
      Participants will undergo blood draws, urine collection, MRI to assess lumbar puncture&#xD;
      safety, and lumbar puncture at the baseline and end-of-study visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">December 31, 2018</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cerebrospinal fluid Aβ42</measure>
    <time_frame>Baseline to End-of-Study (12 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum levels of prostaglandins PGF2α and PGE2</measure>
    <time_frame>Baseline to End-of-Study (12 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urine levels of prostaglandins PGF2α and PGE2</measure>
    <time_frame>Baseline to End-of-Study (12 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebrospinal fluid levels of phosphorylated and total tau protein</measure>
    <time_frame>Baseline to End-of-Study (12 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volumetric brain MRI measurements</measure>
    <time_frame>Baseline to End-of-Study (12 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive measure: Free and Cued Selective Reminding Test (FCSRT)</measure>
    <time_frame>Baseline to End-of-Study (12 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive measure: Trail-making test parts A and B</measure>
    <time_frame>Baseline to End-of-Study (12 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive measure: Naming, both single letter fluency and animal naming.</measure>
    <time_frame>Baseline to End-of-Study (12 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">95</enrollment>
  <condition>Oxidative Stress</condition>
  <arm_group>
    <arm_group_label>AT-001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Yeast-selenium supplement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Yeast supplement devoid of selenium</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>AT-001</intervention_name>
    <arm_group_label>AT-001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Not demented by DSM-IV criteria.&#xD;
&#xD;
          -  English-speaking, to ensure compliance with cognitive testing and study visit&#xD;
             procedures.&#xD;
&#xD;
          -  Montreal Cognitive Assessment (MoCA) score at screening visit ≥24/30.&#xD;
&#xD;
          -  Female participants must not be pregnant or of childbearing potential (surgically&#xD;
             sterile or post-menopausal for &gt;1 year).&#xD;
&#xD;
          -  Stable medical condition for 3 months prior to screening visit in the opinion of the&#xD;
             study physician.&#xD;
&#xD;
          -  Non-diabetic, confirmed by fasting serum glucose &lt;120 mg/dL and on no oral&#xD;
             hypoglycemic agents or insulin treatment.&#xD;
&#xD;
          -  No other clinically significant abnormalities on labs (CBC, chemistry panel, PT/INR,&#xD;
             aPTT, urinalysis).&#xD;
&#xD;
          -  Stable medications for 4 weeks prior to screening.&#xD;
&#xD;
          -  Able to ingest oral medications.&#xD;
&#xD;
          -  Physically acceptable for the study as confirmed by medial history, physical exam,&#xD;
             neurological exam, and clinical tests in the opinion of the study physician.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant neurological disease, such as Parkinson's disease, brain tumor, multiple&#xD;
             sclerosis, or seizure disorder&#xD;
&#xD;
          -  Major depression in the past 12 months (DSM-IV criteria), major mental illness such as&#xD;
             schizophrenia, or recent (in past 12 months) alcohol or substance abuse.&#xD;
&#xD;
          -  History of invasive cancer within the past 2 years (excluding non-melanoma skin&#xD;
             cancer).&#xD;
&#xD;
          -  Contraindications to lumbar puncture (bleeding disorder, platelet count &lt;100,000,&#xD;
             anticoagulant treatment, major structural abnormality or sepsis in the area of the&#xD;
             lumbosacral spine, or previous lower back surgery that would make LP technically&#xD;
             difficult in the opinion of the study physician, hypersensitivity to lidocaine).&#xD;
&#xD;
          -  Contraindications to MRI (pacemaker, shrapnel, metallic implants, etc).&#xD;
&#xD;
          -  Clinically significant abnormalities on labs (CBC, chemistry panel, PT/INR, aPTT,&#xD;
             urinalysis).&#xD;
&#xD;
          -  Use of any investigational agents within 30 days prior to screening.&#xD;
&#xD;
          -  Major surgery within eight weeks prior to the Baseline Visit.&#xD;
&#xD;
          -  Severe unstable major medical illnesses, including uncontrolled cardiac conditions or&#xD;
             heart failure (New York Heart Association Class III or IV).&#xD;
&#xD;
          -  Antiretroviral therapy for human immunodeficiency virus (HIV).&#xD;
&#xD;
          -  Residence in a skilled nursing facility.&#xD;
&#xD;
          -  Blindness, deafness, language difficulties, or any other disability which may prevent&#xD;
             the participant.&#xD;
&#xD;
        Excluded Medications:&#xD;
&#xD;
          -  Experimental drugs.&#xD;
&#xD;
          -  Coumadin, heparin, or any other anticoagulant.&#xD;
&#xD;
          -  Insulin or other hypoglycemic agents.&#xD;
&#xD;
          -  Supplements containing more than 50 µg selenium/day (US RDA) in the 12 weeks prior to&#xD;
             screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard R Murphy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kentucky</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ronan Powers, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Alltech Life Sciences Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gregory A. Jicha, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Kentucky</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kentucky Sanders-Brown Center on Aging Clinic</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>November 2, 2016</study_first_submitted>
  <study_first_submitted_qc>February 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2017</study_first_posted>
  <last_update_submitted>August 15, 2019</last_update_submitted>
  <last_update_submitted_qc>August 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Kentucky</investigator_affiliation>
    <investigator_full_name>Richard Ronan Murphy</investigator_full_name>
    <investigator_title>M.B.B.S., Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>brain</keyword>
  <keyword>health</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

